natgillin/translations-raw huggingface dataset:
Enbrel is used with methotrexate (a medicine that acts on the immune system) in adults with moderate or severe disease who have not responded adequately to other treatments, or on its own if methotrexate is not suitable for the patient.
Enbrel se koristi u kombinaciji s metotreksatom (lijekom koji djeluje na imunosni sustav) u odraslih osoba s umjerenom ili teškom bolesti, a koji nisu odgovarajuće odgovorili na druga liječenja ili kao monoterapija ako metotreksat nije primjeren za liječenje bolesnika.
What is Enbrel?
Što je Enbrel?
Enbrel was also compared with placebo in 51 children with polyarticular juvenile idiopathic arthritis, 205 adults with psoriatic arthritis, 357 adults with ankylosing spondylitis, 1,263 adults and 211 children with plaque psoriasis, as well as in 225 patients with non-radiographic axial spondyloarthritis.
Enbrel je također uspoređen s placebom u 51 djeteta s poliartikularnim juvenilim idiopatskim artritisom, 205 odraslih osoba s psorijatskim artritisom, 357 odraslih osoba s ankiloznim spondilitisom,
It is available as vials containing a powder that is made up into a solution for injection, and as prefilled syringes and pens containing a solution for injection.
Dostupan je kao bočice koje sadrže prašak za pripremu otopine za injekciju, te kao napunjene injekcije i aplikatori koji sadrže otopinu za injekciju.
Enbrel is a medicine that contains the active substance etanercept.
Enbrel je lijek koji sadrži djelatnu tvar etanercept.
In the fifth study, Enbrel on its own or in combination with methotrexate was more effective than methotrexate alone.
U petom ispitivanju, monoterapija Enbrelom ili Enbrel u kombinaciji s metotreksatom bili su učinkoviti od monoterapije metotreksatom.
This messenger is found at high levels in patients with the diseases that Enbrel is used to treat.
Ovaj je glasnik prisutan u velikim koncentracijama u bolesnicima s bolestima za čije je liječenje Enbrel indiciran.
For more information, see the package leaflet.
Za više informacija, pročitajte uputu o lijeku.
What is Enbrel used for?
Za što se Enbrel koristi?
patients aged two to 17 years who have polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis and have not responded adequately to or cannot take methotrexate;
bolesnika u dobi od 17 godina koji imaju poliartritis (pozitivan ili negativan reumatoidni faktor) i produljen oligoartritis te nisu primjereno odgovorili na metotreksat ili ga ne mogu uzimati;
What benefit has Enbrel shown during the studies?
Koje su koristi lijeka Enbrel utvrđene u ispitivanjima?
• severe ankylosing spondylitis (a disease causing inflammation of the joints of the spine) in adults who have not responded adequately to other treatments;
• ozbiljnog aksijalnog spondiloartritisa (bolesti koja uzrokuje upalu zglobova kralježnice) u odraslih osoba koje ne odgovaraju primjereno na druga liječenja;
Patients who take Enbrel must be given the special alert card that summarises important safety information about the medicine.
Bolesnicima koji se liječe Enbrelom treba dati karticu s upozorenjima za bolesnika koja sadži informacije o lijeku.
Enbrel is given by injection under the skin.
Enbrel se primjenjuje supkutanom injekcijom.
How is Enbrel used?
Kako se Enbrel koristi?
adolescents aged 12 to 17 years who have psoriatic arthritis (a disease causing red, scaly patches on the skin and inflammation of the joints) and have not responded adequately to or cannot take methotrexate; adolescents aged 12 to 17 years who have enthesitis-related arthritis and have not responded adequately to or cannot take standard treatment.
adolescenata u dobi od 12 do 17 godina koji imaju psorijatični artritis (bolest koja uzrokuje crvenu, suhu, ljuskavu kožu i upalu zglobova) te nisu primjereno odgovorili na metotreksat ili ga ne mogu uzimati;
For the full list of all side effects reported with Enbrel, see the package leaflet.
Potpuni popis nuspojava zabilježenih pri primjeni lijeka Enbrel, potražite u uputi o lijeku.
How has Enbrel been studied?
Kako se Enbrel ispitivao?
How does Enbrel work?
Kako djeluje Enbrel?
ATCvet code: QC03DA01.
ATCvet kod: QC03DA01.
Wash hands after use.
Po korištenju treba oprati ruke.
Food increases the bioavailability from 80 % to 90 %.
Hrana povećava bioraspoloživost na 80 % do 90 %.
Do not use in animals used for, or intended for use in breeding.
Ne koristiti u životinja koje se koriste za, ili su namijenjene uzgoju.
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu/.
Detaljne informacije o ovom veterinarsko - medicinskom proizvodu su dostupne na web stranici Europske Medicinske Agencije (EMA) http://www.ema.europa.eu/.
If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon.
Ukoliko primijetite ikakve ozbiljne nuspojave ili nuspojave koji nisu spomenute u ovoj uputi molimo da o tome obavijestite vašeg veterinara.
5 to 10 kg 10 to 15 kg 15 to 20 kg 20 to 30 kg 30 to 40 kg 40 to 50 kg 50 to 60 kg
5 do 10 kg 10 do 15 kg 15 do 20 kg 20 do 30 kg 30 do 40 kg 40 do 50 kg 50 do 60 kg
The tablet can either be mixed with a small amount of food offered prior to the main meal, or administered directly into the mouth after feeding.
Tableta se može umiješati u manju količinu hrane koja se daje prije glavnog dijela obroka ili se može dati izravno u usta nakon hranjenja.
Très le Bois 22600 Loudéac France
22600 Loudéac
Although the precise mechanism of action is not yet clearly defined, aldosterone promotes myocardial fibrosis, myocardial and vascular remodelling and endothelial dysfunction.
Iako točan mehanizam djelovanja još nije jasno definiran, aldosteron pospješuje miokardijalnu fibrozu, miokardijalnu i vaskularnu prilagodbu i disfunkciju endotela.
Pharmacotherapeutic group: Aldosterone antagonist.
Farmakoterapijska grupa: Antagonisti aldosterona.
Use within 2 months after first opening the bottle.
Upotrijebiti u roku od 2 mjeseca po prvom otvaranju bočice.
Spironolactone may cause both induction and inhibition of cytochrome P450 enzymes and could therefore affect the metabolism of other drugs utilizing these metabolic pathways.
Spironolakton može uzrokovati i indukciju i inhibiciju citokrom P450 enzima te na taj način djelovati na metabolizam drugih lijekova koji koriste te metaboličke putove.
Date of first authorisation: 20 June 2007 Date of last renewal: 22 May 2012
Datum zadnjeg produljenja odobrenja: 22.5.2012.
After oral administration of spironolactone to dogs, it was demonstrated that the three metabolites achieved levels from 32 % to 49 % of the administered dose.
Nakon peroralnog davanja spironolaktona psima pokazalo se da tri metabolita postižu razinu od 32 % do 49 % od primijenjene doze.
Do not use during pregnancy or lactation.
Ne koristiti tijekom graviditeta i laktacije.
Following oral administration of 2 to 4 mg/kg, absorption increases linearly over the range.
Nakon peroralnog davanja od 2 do 4 mg / kg, absorpcija se povećava linearno.
Spironolactone.
Spironolakton.
Polyamide/aluminium/polyvinyl chloride//aluminium blisters containing 10 tablets.
Poliamid / aluminij / polivinil klorid / aluminijski blisteri koji sadržavaju 10 tableta.
Spironolactone is mainly excreted via its metabolites.
Spironolakton se uglavnom izlučuje putem svojih metabolita.
Artificial beef flavour Compressible sugar Magnesium stearate
Umjetna aroma govedine Stlačivi šećer Magnezijev stearat
Sodium laurilsulfate Microcrystalline cellulose Povidone
Natrijev lauril sulfat Mikrokristalična celuloza Povidon
30 tablets 180 tablets
180 tableta
As the therapeutic index for digoxin is very narrow, it is advisable to monitor closely dogs receiving both digoxin and spironolactone.
Kako je terapeutski indeks digoksina vrlo uzak preporuča se pažljivo praćenje pasa koji primaju digoksin zajedno sa spironolaktonom.
For a full list of excipients, see section 6.1.
Popis pomoćnih tvari vidi u odjeljku 6.1
Do not use in conjunction with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in dogs with renal insufficiency (kidney impairment/dysfunction).
Ne koristiti zajedno s nesteroidnim protuupalnim lijekovima (NSPUL) u pasa s bubrežnom insuficijencijom (umanjenom funkcijom / disfunkcijom bubrega).
Dogs treated concomitantly with spironolactone and NSAIDs should be correctly hydrated.
Psi koji se istodobno liječe sa spironolaktonom i NSULP trebaju biti pravilno rehidrirani.
This is thought to be due to activation of feedback mechanisms without adverse clinical consequence.
To se pripisuje aktivaciji mehanizma povratne sprege bez štetnih kliničkih posljedica.
Spironolactone is a natriuretic drug (historically described as a soft diuretic).
Spironolakton je natrijuretički lijek (poznat je kao blagi diuretik).
In experimental models in dogs, it was shown that long term therapy with an aldosterone antagonist prevents progressive left ventricle dysfunction and attenuates left ventricle remodelling in dogs with chronic heart failure.
U eksperimentalnim modelima u pasa, dokazano je da dugotrajnije liječenje antagonistima aldosterona sprječava progresivnu disfunkciju i slabi preoblikovanje lijeve klijetke u pasa s kroničnim zatajenjem srca.
Cardboard box containing 3 or 18 blisters of 10 tablets.
Kartonska kutija s 3 ili 18 blistera po 10 tableta.
May cause skin sensitisation: people with known hypersensitivity to spironolactone should avoid contact with the veterinary medicinal product.
Proizvod može uzrokovati kožne reakcije: osobe preosjetljive na spironolakton trebaju izbjegavati kontakt s ovim veterinarsko - medicinskim proizvodom.
In a clinical study investigating the survival time in dogs with congestive heart failure, there was a 65% reduction in the relative risk of mortality at 15 months in dogs treated with spironolactone in combination with standard therapy compared to dogs treated with standard therapy alone.
U kliničkom ispitivanju vremena preživljavanja pasa s kongestivnim zatajenjem srca rezultati su pokazali smanjenje rizika smrtnosti za 65 % kroz 15 mjeseci u pasa liječenih sipronolaktonom u kombinaciji sa standardnom terapijom u odnosu na pse liječene isključivo standardnom terapijom (smrtnost je klasificirana kao smrt ili eutanazija zbog zatajenja srca).
Do not use during pregnancy and lactation, laboratory studies in species (rat, mouse, rabbit and monkey) have shown evidence of developmental toxicity.
Laboratorijska istraživanja na različitim životinjskim vrstama (štakorima, miševima, kunićima i majmunima) pokazale su pojavu razvojne toksičnosti.
6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products
6.6 Posebne mjere predostrožnosti za odlaganje neupotrjebljenog veterinarsko - medicinskog proizvoda ili otpadnih materijala dobivenih primjenom tih proizvoda
Tablet.
Tablete.
Furosemide and pimobendan have been used together with Spironolactone Ceva in dogs with heart failure without any clinical evidence of adverse reactions.
Furosemid i pimobendan korišteni su zajedno sa Prilactonom u pasa sa zatajenjem srca, bez kliničkih manifestacija nuspojava.
Lactose monohydrate Cellulose, microcrystalline Crospovidone Povidone K30
Laktoza monohidrat Mikrokristalična celuloza Krospovidon Povidon K30
1 to 2.5 kg
1 do 2.5 kg
It is therefore recommended to induce vomiting, gastric lavage (depending on risk assessment) and monitor electrolytes.
Stoga se preporučuje poticanje povraćanja, ispiranje želuca (ovisno o procjeni rizika) te praćenje elektrolita.
Do not use after the expiry date which is stated on the carton and blister label after EXP.
Ne koristiti nakon isteka roka trajanja označenog na kutiji i bočici nakon EXP.
The mean volumes of distribution (Vss) of 7α-thiomethyl-spironolactone and canrenone are approximately 153 litres and 177 litres, respectively.
Prosječne količine distribucije (Vss) 7α - tiometil - spironolaktona i kanrenona su oko 153 litre, odnosno 177 litara.
Beef flavouring Mannitol
Aroma govedine Manitol
2.5 to 5 kg
2.5 do 5 kg
After oral administration of radiolabelled spironolactone to the dog, 70 % of the dose is recovered in faeces and 20 % in the urine.
Nakon peroralnog davanja radiološki označenog spironolaktona psima 70 % primljene doze izlučeno je izmetom, a 20 % mokraćom.
Spironolactone is rapidly and completely metabolised by the liver into its active metabolites, 7αthiomethyl-spironolactone and canrenone, which are the primary metabolites in the dog.
Spirinolakton se brzo i u potpunosti metabolizira u jetri u svoje aktivne metabolite, 7α - tiometilspironolakton i kanrenon, koji su primarni metaboliti u pasa.
In case of an accidental massive ingestion by a dog, there is no specific antidote or treatment.
U pasa, kod slučajnog gutanja veće količine lijeka, ne postoji specifičan lijek ili liječenje.
Spironolactone decreases digoxin elimination and hence raises digoxin plasma concentration.
Spironolakton umanjuje eliminaciju digoksina te tako povećava njegovu koncentraciju u plazmi.
The tablets contain beef flavouring to improve palatability, and a study conducted in healthy dogs showed that they were voluntarily and fully consumed 75% of the time.
Tablete imaju aromu govedine kako bi im se poboljšao okus, a pokusi na zdravim psima su pokazali da 75 % pasa dobrovoljno u cijelosti pojede tabletu.
When used in combination with ACE-inhibitors, spironolactone may counteract the effects of “aldosterone escape”.
Kada se koristi u kombinaciji s ACE inhibitorima, spironolakton može neutralizirati pojavu koju nazivamo “bijeg aldosterona”.
Plasma clearance of canrenone is 1.45±0.39 l/h/kg and 7α-thiomethyl-spironolactone is 0.89±0.44 l/h/kg.
Plazmatski klirens kanrenona je 1.45 ± 0.39 litara / h / kg, a 7α - tiometl - spironolaktona 0.89 ± 0.44 litara / h / kg.
The administration of either deoxycorticosterone or NSAIDs with spironolactone may lead to a moderate reduction of the natriuretic effects (reduction of urinary sodium excretion) of spironolactone.
Davanje dezoksikortikosterona ili NSPUL sa spironolaktonom može dovesti do umjerenog smanjenja natrijuretičkog učinka (smanjenje izlučivanja natrija mokraćom) spironolaktona.
In the kidney, spironolactone inhibits the aldosterone-induced sodium retention leading to increase in sodium and subsequently water excretion, and potassium retention.
U bubregu, spironolakton inhibira aldosteronski inducirano zadržavanje natrija što uzrokuje povećano izlučivanje natrija uz posljedično izlučivanje vode i zadržavanje kalija.
After multiple oral doses of 2 mg spironolactone/ kg for 10 consecutive days, no accumulation is observed.
Nakon višekratnog peroralnog davanja spironolaktona u dozi od 2 mg / kg kroz 10 uzastopnih dana, nije uočeno akumuliranje.
A slight increase in aldosterone blood levels may be observed in animals on treatment.
U liječenih životinja može se uočiti blagi porast aldosterona u krvi.
EXP: {month/year} Use within 2 months after first opening the bottle.
Koristiti unutar 2 mjeseca po prvom otvaranju bočice.
Disposal: read package leaflet.
Odlaganje: Pročitati uputu o VMP.
CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES
SADRŽAJ: TEŽINA, VOLUMEN IL BROJ DOZA 30 tableta
4.2 Indications for use, specifying the target species
4.2 Indikacije za primjenu u kojima se navode ciljne vrste životinja
6.2 Incompatibilities
6.2 Inkopatibilnost
Spironolactone and its active metabolites (including 7α-thiomethyl-spironolactone and canrenone) act as specific antagonists of aldosterone, and exert their effects by binding competitively to the mineralocorticoid receptor located in the kidneys, heart and blood vessels.
Spironolakton i njegovi aktivni metaboliti (uključujući 7α - tiometil - spironolakton i kanrenon) djeluju kao specifični antagonisti aldosterona, vežući se kompetitivno na mineralokortikoidne receptore koji se nalaze u bubrezima, srcu i krvnim žilama.
The pharmacokinetics of spironolactone are based on its metabolites, as the parent compound is unstable at assay.
Farmakokinetika spironolaktona temelji se na njegovim metabolitima jer je sam spironolakton nestabilan pri testiranjima.
As spironolactone has an antiandrogenic effect, it is not recommended to administer the veterinary medicinal product to growing dogs.
Spironolakton ima antiandrogeni učinak, pa se ne preporuča njegovo davanje psima u rastu.
There may be a dose related hypertrophy of the adrenal zona glomerulosa at high dose rates.
Pri visokim dozama može se, ovisno o dozi, javiti hipertrofija adrenalne zone glomerulose.
After administration of up to 10 times the recommended dose (20 mg/kg) to healthy dogs, dosedependent adverse effects were noted (see section 4.6).
Nakon primjene i do 10 puta veće doze od preporučene (20 mg / kg) u zdravih pasa, nisu primijećeni štetni učinci ovisni o dozi (vidjeti dio 4.6).
Bottle containing 30 tablets packed in a cardboard box.
Bočica sadržava 30 tableta i nalazi se u kartonskoj kutiji.
Symptomatic treatment, e.g., fluid therapy, should be provided.
Potrebno je provesti simptomatsko liječenje npr. rehidraciju.
Partially used tablets should be stored in the original blister and used within 7 days.
Prelomljenu tabletu vratiti u originalni blister i iskoristiti unutar 7 dana.
For use in combination with standard therapy (including diuretic support, where necessary) for the treatment of congestive heart failure caused by valvular regurgitation in dogs.
Za primjenu pri standardnoj terapiji (uključujući po potrebi diuretike) kod kongestivnog zatajenja srca u pasa, uzrokovanog valvularnom regurgitacijom .
The renal effects of spironolactone and its metabolites lead to a decrease in extracellular volume and consequently in a decrease of cardiac preload and left atrial pressure.
Djelovanje spironolaktona i njegovih metabolita u bubregu dovode do smanjenja izvanstaničnog volumena, posljedično do smanjenog dotoka u srce te smanjenog pritiska u lijevom atriju.
Concomitant administration of spironolactone with ACE-inhibitors and other potassium-sparing drugs (as angiotensin receptor blockers, ß-blockers, calcium channels blockers, etc) may potentially lead to hyperkalaemia (see section "Special precautions for use in animals").
Istodobna primjena spironolaktona s ACE inhibitorima i drugim lijekovima koji smanjuju izlučivanje kalcija (kao što su blokatori angiotenzinskih receptora, ß - blokatori, blokatori kalcijskih kanala (BKK) i sl.) može dovesti do hiperkalijemije (vidi "Posebne mjere predostrožnosti za primjenu na životinjama").
However, in dogs with renal impairment regular monitoring of renal function and serum potassium levels is recommended as there may be an increased risk of hyperkalaemia.
Međutim, kod pasa s oštećenjem bubrega preporuča se zbog mogućeg povećanog rizika od hiperkalijemije, redovito praćenje funkcije bubrega te kalija u serumu.
Cardboard box of 1 bottle of 30 tablets
PODACI NA VANJSKOM PAKOVANJU Kartonska kutija s 1 bočicom s 30 tableta
Oral use.
Peroralno davanje.
SPECIAL WARNING(S), IF NECESSARY
12. POSEBNO(A) UPOZORENJE(A)
Concomitant administration of spironolactone with ACE-inhibitors and other potassium-sparing drugs (as angiotensin receptor blockers, ß-blockers, calcium channels blockers…etc) may potentially lead to hyperkalaemia (see section 4.5).
Istodobna primjena spironolaktona s ACE inhibitorima i drugim lijekovima koji smanjuju izlučivanje kalcija (kao što su blokatori angiotenzinskih receptora, ß - blokatori, blokatori kalcijskih kanala (BKK) i sl.) može dovesti do hiperkalijemije (vidi 4.5).
In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.
Pri slučajnom gutanju lijeka potrebno je odmah potražiti liječnički savjet uz predočenje upute za korištenje.
After administration of up to 10 times the recommended dose (20 mg/kg) to healthy dogs, dosedependent adverse effects were noted (see section "Adverse Reactions").
Nakon primjene i do 10 puta preporučena doza (20 mg / kg) u zdravih pasa, nisu primijećeni štetni učinci ovisni o dozi (vidi „Nuspojave“)
Mean Cmax of 382 μg/l and 94 μg/l are achieved for the primary metabolites, 7αthiomethyl-spironolactone and canrenone, after 2 and 4 hours, respectively.
Prosječna vršna koncentracija, Cmax od 382 g / litri i 94 g / litri su postiže se za primarne metabolite, 7α - tiometilspironolakton i kanrenon, nakon 2, odnosno 4 sata, Stabilno stanje postiže se do drugog dana.
Blister - 10 mg tablets, 40 mg tablets and 80 mg tablets
ILI TRAKAMA Blister - tablete od 10 mg, tablete od 40 mg i tablete od 80 mg
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
IME I ADRESA NOSITELJA ODOBRENJA ZA STAVLJANJE U PROMET
Unlike in humans, an increased incidence of hyperkalaemia was not observed in clinical trials performed in dogs with this combination.
Za razliku od ljudi, u kliničkim ispitivanjima s ovom kombinacijom lijekova, provedenim u pasa, nije uočena povećana učestalost hiperkalijemije.
OTHER INFORMATION Pack size:
Veličina pakovanja:
As spironolactone undergoes extensive hepatic (liver) biotransformation, care should be taken when using the veterinary medicinal product in dogs with liver dysfunction.
Kako spironolakton prolazi opsežnu biotransformaciju u jetri potrebno ga je oprezno koristiti u liječenju pasa s jetrenom disfunkcijom.
Spironolactone Ceva 10 mg contains 10 mg spironolactone Spironolactone Ceva 40 mg contains 40 mg spironolactone Spironolactone Ceva 80 mg contains 80 mg spironolactone
Spironolactone Ceva 10 mg sadržava 10 mg spironolaktona Spironolactone Ceva 40 mg sadržava 40 mg spironolaktona Spironolactone Ceva 80 mg sadržava 80 mg spironolaktona
Administer 2 mg/kg of body weight of spironolactone once daily.
Spironolakton se daje jednom dnevno u dozi od 2 mg / kg.
Partially used tablets should be stored in the original bottle.
Neupotrjebljene dijelove tableta treba čuvati u originalnoj bočici.
A reversible prostatic atrophy is often observed in entire male dogs.
Reverzibilna atrofija prostate česta je u nekastriranih mužjaka.
Monitoring of their renal function and plasma potassium levels is recommended before initiation and during treatment with combined therapy (see section 4.3).
Preporuča se prije početka i tijekom kombiniranog liječenja pratiti funkciju bubrega te razinu kalija u serumu (vidi 4.3).
EXP: {month/year} Partially used tablets to be used within 7 days.
Neupotrjebljene dijelove tableta treba upotrijebiti unutar 7 dana.
Pack sizes
Très le Bois
Monitoring of their renal function and plasma potassium levels is recommended before initiation and during treatment with combined therapy (see section "Contraindications").
Preporuča se prije početka i tijekom kombiniranog liječenja pratiti funkciju bubrega te razinu kalija u serumu (vidi “Kontraindikacije”).
Shelf life of the veterinary medicinal product as packaged for sale: 3 years 2 months after first opening the bottle.
U originalnom pakiranju: 3 godine Po prvom otvaranju bočice: 2 mjeseca
Do not use in dogs suffering from hypoadrenocorticism, hyperkalaemia or hyponatraemia.
Ne koristiti u pasa sa smanjenom funkcijom nadbubrežne žlijezde (hipoadrenokorticizam), povećanom razinom kalija (hiperkalijemija) ili smanjenom količinom natrija (hiponatremija) u serumu.
Kidney function and serum potassium levels should be evaluated before initiating combined treatment with spironolactone and Angiotensin Converting Enzyme (ACE) inhibitors.
Prije početka kombiniranog liječenja spironolaktonom i inhibitorima angiotenzin konvertirajućeg enzima (ACE inhibitori) potrebno je kontrolirati funkciju bubrega te razinu kalija u serumu.
Partially used tablets should be stored in the original blister.
Neupotrjebljene dijelove tableta treba čuvati u originalnom blisteru.
Shelf life of the veterinary medicinal product as packaged for sale: 3 years Partially used tablets to be used within 7 days.
U originalnom pakiranju: 3 godine Neupotrjebljene dijelove tableta treba upotrijebiti unutar 7 dana.
For animal treatment only - to be supplied only on veterinary prescription.
Izdaje se samo na veterinarski recept.
EU/2/07/074/005 (3 blisters of 10 tablets) EU/2/07/074/006 (18 blisters of 10 tablets)
EU/2/07/074/005 (3 blistera po 10 tableta) EU/2/07/074/006 (18 blistera po 10 tableta)
4.5 Special precautions for use Special precautions for use in animals
4.5 Posebne mjere predostrožnosti za primjenu